📊 Adjusted models: HbA1c remains linked to pain

In a cross-sectional study of 172 adults with Type 2 Diabetes (T2DM) in outpatient clinics in northern Peru, neuropathic pain was present in 50% and higher HbA1c remained linked to neuropathic pain in adjusted models (both as ≥7% and as a continuous measure). Dyslipidemia and hypertension were also independently associated.

Why It Matters To Your Practice

• Neuropathic pain is common in T2DM and can drive sleep disruption, functional decline, and higher visit burden.

• This study supports that glycemic control (HbA1c) is independently associated with painful neuropathic symptoms—not just neuropathy in general.

• Comorbid hypertension and dyslipidemia may co-travel with neuropathic pain risk, reinforcing the need for comprehensive cardiometabolic management.

Clinical Benefits

• Use HbA1c trends as a practical flag to prompt neuropathic pain screening (e.g., targeted symptom questions or a validated tool like S-LANSS when available).

• When HbA1c is ≥7% or persistently rising, consider proactively assessing for painful neuropathy even if patients don’t volunteer symptoms.

• Finding neuropathic pain earlier can speed initiation of multimodal management (glycemic optimization plus evidence-based analgesic strategies and foot-care counseling).

Managing Risks

• A cross-sectional design cannot prove causality; avoid framing HbA1c reduction as guaranteed pain relief.

• Neuropathic pain was identified by questionnaire, not confirmatory neurodiagnostic testing—consider differential diagnoses (radiculopathy, B12 deficiency, alcohol-related neuropathy, CKD-related neuropathy).

• Medication choices for neuropathic pain can raise safety concerns (sedation, falls, drug interactions); tailor to age, renal function, and comorbidities.

The Bottom Line

• In adults with T2DM, higher HbA1c remained independently linked to neuropathic pain after adjustment, with pain reported in 50% of participants.

• For NPs and PAs: treat suboptimal glycemic control as a cue to screen for neuropathic pain and address cardiometabolic comorbidities alongside symptom management.